HIF1A and neoplasm: Additionally, the analysis of HIF-1α mRNA expression levels and HIF-1α protein assays confirmed that the nanocomposite effectively inhibited both mRNA expression and protein translation synchronously; it also exhibited a significant tumour inhibitory rate of 77.99% in vivo, underscoring the potential of this delivery system for antitumor therapy.